

## Technology Advisory Committee C Interests Register

**Topic: Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD positive acute myeloid leukaemia [ID4042]**

**Publication Date: 23/10/2024**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
<b>Pedro Saramago Goncalves</b>	Committee Member	Financial Interests  Professional Interest	Dr Goncalves is currently involved in some health economics advisory work for Alira Health. Alira is putting together a clinical and cost-effectiveness dossier for Accord Healthcare for a product in the Small Cell Lung Cancer disease area, i.e. an unrelated disease area to that of quizartinib.  Dr Goncalves is employed with CRD which is the EAG for this appraisal but has not been involved in any work for this appraisal.	06/08/2024	It was agreed that Pedro Saramago Goncalves' declaration would not prevent him from participating in discussions on this appraisal.
<b>Kate Ren</b>	Committee Member	Financial Interests	Kate has provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area	06/08/2024	It was agreed that Kate Ren's declaration would not prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			(Tofacitinib for Moderate-to-Severe Ulcerative Colitis).		
<b>Elizabeth Thurgar</b>	Committee Member	Financial Interests	Elizabeth is currently providing consultancy advice to Pfizer (a comparator company) in an unrelated condition, non-small cell lung cancer.	06/08/2024	It was agreed that Elizabeth Thurgar's declaration would not prevent her from participating in discussions on this appraisal.
<b>Dr Priyanka Mehta</b>	Clinical Expert	Financial Interests	Dr Mehta has received consultancy fees and an honorarium fee for a speaking engagement from Daiichi Sankyo and Jazz Pharmaceuticals, alongside speaker fees from Pfizer.	06/08/2024	It was agreed that Dr Mehta's declaration would not prevent her from providing expert advice to the committee
<b>Professor Steven Knapper</b>	Clinical Expert	Financial Interests	Professor Knapper has worked intermittently with their nominating organisation - Leukaemia Care - over the last 5-6yrs providing help with patient support literature, patient webinars etc. Leukaemia Care has received funding from Celgene, Jazz Pharmaceuticals, Novartis and	06/08/2024	It was agreed that Professor Knapper's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Pfizer. Professor Knapper has also received speaker fees from Astellas.		
<b>Charlotte Crowley</b>	<i>Patient Expert</i>	Financial Interests	Charlotte Crowley's employer and nominating organisation Leukaemia Care has received funding and honorarium from Celgene, Jazz Pharmaceuticals, Novartis and Pfizer. This funding was related to core patient activities for the organisation. Charlotte Crowley has also received honorarium for speaking opportunity with Pfizer.	06/08/2024	It was agreed that Charlotte Crowley's declaration would not prevent her from providing expert advice to the committee